BioNTech (NASDAQ:BNTX) Trading Up 7.4% – Here’s What Happened

BioNTech SE Sponsored ADR (NASDAQ:BNTX) traded up 7.4% during mid-day trading on Friday . The stock traded as high as $120.33 and last traded at $119.05. Approximately 1,254,472 shares were traded during trading, an increase of 16% from the average daily volume of 1,084,099 shares. The stock had previously closed at $110.89.

Key Stories Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech benefited from renewed momentum across mRNA stocks. The sector’s moves continued to reflect market repricing of a recent cancer-vaccine trial readout, even though no new clinical information was released Friday. Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
• Positive Sentiment: The company announced that it will present new lung-cancer data at the IASLC 2026 World Conference on Lung Cancer. Investors may view the planned updates on pumitamig and elfetabart drozuntecan, including first global data for the combination, as potential catalysts for BioNTech’s longer-term oncology strategy. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data
• Neutral Sentiment: Analyst commentary on BioNTech remains mixed, suggesting investors do not have a clear consensus on the shares’ valuation or outlook. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Neutral Sentiment: Unusually high options activity indicates elevated trading interest and expectations for volatility, but it does not by itself establish a change in BioNTech’s fundamental outlook. BioNTech Target of Unusually High Options Trading
• Negative Sentiment: The recent mRNA rally has been highly volatile; BioNTech pulled back during the prior session as investors reversed part of the sector’s earlier surge. This creates a risk that today’s strength is driven more by trading sentiment than company-specific fundamentals. Moderna Sinks 18% After Cancer Vaccine Rally, BioNTech Falls

Analysts Set New Price Targets

Several brokerages have commented on BNTX. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Berenberg Bank reduced their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Wells Fargo & Company lowered their target price on BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and an average target price of $127.81.

BioNTech Stock Performance

The company has a market capitalization of $29.48 billion, a P/E ratio of -14.89 and a beta of 1.27. The company’s 50 day moving average is $93.43 and its 200-day moving average is $95.79. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company’s revenue was down 59.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.60) EPS. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

BioNTech declared that its board has initiated a stock buyback plan on Thursday, May 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Institutional Trading of BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Larson Financial Group LLC raised its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the last quarter. EFG International AG purchased a new stake in shares of BioNTech in the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. Finally, Vestcor Inc purchased a new position in shares of BioNTech in the 4th quarter worth about $153,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.